MedTrace Logo

Targeted Microbiome Transplant in Atopic Dermatitis

NCT03151148 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2020-08-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the safety and effectiveness of a new therapy, commensal lotion containing infection fighting bacteria, on decreasing or eliminating the infection causing bacteria found on the skin of Atopic Dermatitis (AD) patients.

Conditions

  • Atopic Dermatitis (AD)

Interventions

BIOLOGICAL

TMT Lotion

TMT product and Vegetable glycerin-Cetaphil®

DRUG

Placebo Lotion

Cetaphil® moisturizing lotion and vegetable glycerin

Sponsors & Collaborators

  • Atopic Dermatitis Research Network

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Richard Gallo, M.D., Ph.D. · University of California, San Diego: Dermatology Clinical Trials Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-28
Primary Completion
2019-05-14
Completion
2019-06-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03151148 on ClinicalTrials.gov